2. Date Exercisable and Expiration Date (Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)
4. Conversion or Exercise Price of Derivative Security
5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)
6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable
Expiration Date
Title
Amount or Number of Shares
Employee Stock Option - Right to Buy
(1)
03/06/2023
Common Stock
1,729
30.9
D
Employee Stock Option - Right to Buy
(1)
03/06/2023
Common Stock
526
30.9
D
Employee Stock Option - Right to Buy
(2)
03/05/2024
Common Stock
2,547
55.84
D
Employee Stock Option - Right to Buy
(3)
03/04/2025
Common Stock
4,111
55.61
D
Employee Stock Option - Right to Buy
(4)
02/17/2026
Common Stock
4,739
46.27
D
Employee Stock Option - Right to Buy
(5)
03/03/2027
Common Stock
5,694
45.18
D
Employee Stock Option - Right to Buy
(6)
03/02/2028
Common Stock
7,876
40.97
D
Restricted Stock Units
(7)
(7)
Common Stock
1,611
0.00
D
Restricted Stock Units
(8)
(8)
Common Stock
8,055
0.00
D
Employee Stock Option - Right to Buy
(9)
03/01/2029
Common Stock
6,267
27.45
D
Restricted Stock Units
(10)
(10)
Common Stock
6,995
0.00
D
Restricted Stock Units
(11)
(11)
Common Stock
13,115
0.00
D
Employee Stock Option - Right to Buy
(12)
03/02/2030
Common Stock
8,119
17.48
D
Restricted Stock Units
(13)
(13)
Common Stock
15,103
0.00
D
Restricted Stock Units
(14)
(14)
Common Stock
18,879
0.00
D
Explanation of Responses:
1. These options vested on March 6, 2016.
2. These options vested on March 5, 2017.
3. These options vested on March 4, 2018.
4. These options vested on February 17, 2019.
5. These options vested on March 3, 2020.
6. 2,626 of these options vested on March 2, 2019, 2,625 vested on March 2, 2020 and 2,625 will vest on March 2, 2021.
7. Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. ('Viatris'). These RSUs will vest on March 2, 2021.
8. Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest in full on March 2, 2021.
9. One-third of these options vested on March 2, 2020 and one-third will vest on each of March 2, 2021 and March 2, 2022.
10. Each RSU represents the right to receive one share of common stock of Viatris. 3,497 of these RSUs will vest on March 2, 2021 and 3,498 will vest on March 2, 2022.
11. Each RSU represents the right to receive one share of common stock of Viatris. These RSUs will vest in full on March 2, 2022.
12. 2,707 of these options will vest on March 2, 2021 and 2,706 will vest on each of March 2, 2022 and March 2, 2023.
13. Each RSU represents the right to receive one share of common stock of Viatris. 5,035 of these RSUs will vest on March 2, 2021 and 5,034 will vest on each of March 2, 2022 and March 2, 2023.
14. Each RSU represents the right to receive one share of common stock of Viatris. These RSUs will vest in full on March 2, 2023.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Kevin Macikowski, by power of attorney
03/04/2021
** Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Attachments
Original document
Permalink
Disclaimer
Viatris Inc. published this content on 04 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2021 23:32:08 UTC.
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the Companyâs ARV franchise. Its portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas, including key brands and generics, including complex products. It operates around 40 manufacturing sites worldwide that produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.